In colorectal cancer (CRC), the morphology at the invasive tumour margin is believed to reflect tumour dynamics with pro- and anti-tumour effects, thereby rendering important prognostic information ([@bib22]).

Tumour budding, defined as the presence of isolated single cells or small clusters of cells (composed of fewer than five cells) ([@bib21]; [@bib17]), has repeatedly been associated with adverse outcome ([@bib21]; [@bib19]; [@bib2]; [@bib17]; [@bib6]; [@bib16]; [@bib1]; [@bib12]; [@bib7]), while marked peritumoural (and intratumoural) inflammation has been associated with favourable outcome ([@bib8]). Of note, the anti-tumour activity of inflammation, particularly lymphocytes and neutrophils, may lead to the destruction of tumour glands and, ultimately, the presence of isolated cells or small clusters of cells scattered in the tumour stroma, which has to be differentiated from true tumour budding.

Our study aimed to analyse the relationship between tumour budding and peritumoural inflammation in a large cohort of CRC patients. Specifically, we were interested to answer the question whether patients with both high-grade budding and high-grade inflammation have a prognosis comparable to patients with low-grade budding.

Materials and methods
=====================

Study cohort
------------

The study cohort comprised 381 patients (166 males, 215 females; median age 70.1 years) and has been described in detail elsewhere ([@bib4]).

Decision for adjuvant therapy was based upon American Joint Committee on Cancer (AJCC)/Union Internationale Contre le Cancer (UICC) tumour stage. Thus, patients with stage III disease received 5-fluorouracil/folinic acid following the Mayo Clinic recommendations ([@bib15]), while patients lacking nodal metastasis (stages I and II) remained without adjuvant treatment. Patients with node-positive rectal cancer received adjuvant radiotherapy. Patients who underwent neoadjuvant therapy were excluded.

The follow-up regimen, which included laboratory testing, abdominal ultrasound, chest X-ray as well as pelvic computerized tomography for rectum cancer patients, has been referred to in detail in our previous publication ([@bib4]). Local or systemic relapse defined disease progression. Patients were followed after resection until death or time of last follow-up. The Ethics Committee of the Medial University of Graz, Austria, provided institutional Review Board approval.

Histopathology
--------------

All histological slides were independently reviewed by two gastrointestinal pathologists (MJP and CL), who were unaware of clinical, in particular follow-up data. Tumour stage was assessed based upon the 7th edition of the AJCC/UICC TNM classification ([@bib20]).

The extent of tumour budding was assessed on haematoxylin- and eosin-stained slides as described previously ([@bib1]). In the tumour area with highest budding intensity, the number of isolated single cells or small clusters of less than five cells at the invasive tumour margin was counted at × 200 magnification (field of vision: 0.95 mm^2^; Olympus BX45, × 20/0.40, Tokyo, Japan). For statistical comparison, tumours were divided into two groups based upon the number of budding foci: counts of 0--9 were classified as low-grade, while counts of 10 or more foci were classified as high-grade budding ([@bib21]; [@bib1]).

The overall inflammatory reaction and the amount of lymphoid cells, neutrophilic and eosinophilic granulocytes as well as macrophages were assessed using the four-degree scale introduced by [@bib8]: a score 0 indicated 'no increase of inflammatory cells\'. Score 1 indicated 'mild and patchy increase of inflammatory cells at the invasive margin, but no destruction of invading cancer cell islets by the inflammatory cells\'. A score of 2 was given when inflammatory cells formed a 'band-like infiltrate at the invasive margin with some destruction of cancer cell islets by inflammatory cells\'. A score of 3 indicated a 'very prominent inflammatory reaction, forming a cup-like zone at the invasive margin, and destruction of cancer cell islets was frequent and invariably present\'.

Statistical analysis
--------------------

Associations between tumour budding and other tumour features were analysed using the *χ*^2^-test. Progression-free and cancer-specific survival was determined using the Kaplan--Meier method and compared by the log-rank test. For multivariable testing, Cox\'s proportional hazards regression models were performed. All *P*-values were two sided with significance at *P*\<0.05. All statistical procedures were done with SPSS version 20.0 software (IBM, Armonk, NY, USA). This study complied with the REporting recommendations for tumour MARKer prognostic studies (REMARK) criteria ([@bib13]).

Results
=======

Overall, 221 (58%) tumours showed low-grade, 160 (42%) tumours high-grade budding. The extent of tumour budding was associated positively with T and N classification and tumour grade, however, inversely with the extent of peritumoural inflammation ([Table 1](#tbl1){ref-type="table"}). In all, 167 (44%) tumours showed no increase or only a mild and patchy increase of inflammatory cells at the invasive tumour margin, but no destruction of invading cancer cell islets (scores 0--1), whereas in 214 (56%) tumours a band-like mixed inflammatory infiltrate with at least some destruction of cancer cell islets was seen (scores 2--3). When analysis was restricted to tumours with high-grade budding, 82 (51%) cases showed mild inflammation (scores 0--1) and 78 (49%) marked inflammation (scores 2--3; [Figure 1](#fig1){ref-type="fig"}).

Follow-up information was available for 350 (92%) patients (median 45 months, range 1--182). In all, 141 (37%) patients developed progressive disease, and 118 (34%) died from cancer.

Tumour budding was significantly associated with poor progression-free (*P*\<0.001) and cancer-specific (*P*\<0.001) survival in our cohort. In multivariate analyses, tumour budding proved to be a predictor of both progression-free (hazard ratio (HR) 1.67, 95% confidence interval (CI) 1.11--2.51; *P*=0.014) and cancer-specific (HR 1.93, 95% CI 1.25--2.97; *P*=0.003) survival, independent of T and N classification, tumour grade, lymphatic and venous invasion. When peritumoural inflammation was added to analysis, tumour budding retained statistical significance, whereas for inflammation no independent impact on outcome was noted (data not shown).

Combined analysis of tumour budding and inflammatory cell reaction lead to the following results: patients with high-grade budding and marked inflammation had a better outcome, with respect to both progression-free (*P*\<0.001) and cancer-specific survival (*P*\<0.001), than patients with high-grade budding and only mild inflammation. Outcome in these cases, however, was still worse compared with patients with low-grade budding, in which the extent of peritumoural inflammation had no further prognostic effect ([Figure 2](#fig2){ref-type="fig"}). This was confirmed in multivariate analysis: in cancers with high-grade budding marked inflammation proved to be a predictor of favourable progression-free (HR 0.59, 95% CI 0.38--0.92; *P*=0.021) and cancer-specific (HR 0.58, 95% CI 0.36--0.93; *P*=0.024) survival, independent of T and N classification, tumour grade, lymphatic and venous invasion. In cancers with low-grade budding no independent impact on outcome was noted (data not shown).

Discussion
==========

Tumour budding (single tumour cells or small tumour cell clusters) at the invasion front of CRC is an adverse prognostic indicator that has been linked to epithelial--mesenchymal transition, an important mechanism for cancer progression ([@bib12]). Ki67, caspase-3 and M30 staining is absent in most tumour buds, suggesting decreased proliferation and apoptosis ([@bib3]). Active immunosurveillance in the tumour microenvironment has been associated with low-frequency tumour budding and improved outcome. According to [@bib9], tumour buds may however evade immune recognition through downregulation of membranous major histocompatibility complex (MHC) class I, thereby conferring an aggressive phenotype with the potential to disseminate and metastasize ([@bib22]). On the molecular level, tumour budding is correlated inversely with microsatellite instability (MSI-H) ([@bib23]).

Different methods to assess tumour budding have been introduced ([@bib5]; [@bib7]). Peritumoral inflammatory cells, including histiocytes, can be difficult to differentiate from tumour buds, and may sometimes obscure the underlying budding. Immunohistochemistry for anti-cytokeratin may help to highlight tumour buds in this setting ([@bib14]) and may also improve interobserver agreement ([@bib10]).

Marked peritumoural inflammation is a marker of favourable outcome in CRC ([@bib8]; [@bib18]). As indicated above, the anti-tumour activity of the overall inflammatory cell reaction, driven mainly by neutrophils and macrophages, may lead to unspecific destruction of cancer cell islets, thereby generating isolated single cells or small clusters of cells. This phenomenon has to be differentiated, pathogenetically, from the specific anti-tumour response characterized by tumour-infiltrating T lymphocytes, which specifically target (pre-existing) tumour buds, described by [@bib11] as 'nipping in the bud\'.

In our study we were able to show that patients with high-grade budding and marked inflammation had a significantly better outcome compared with patients with high-grade budding and only mild inflammation, which may be due to inflammation-related destruction of cancer cell islets at the tumour margin. Outcome of cases with high-grade budding and marked inflammation, however, was still significantly worse compared with patients with low-grade budding. These data, which were evident in univariate and multivariate analyses, clearly confirm the outstanding value of tumour budding as a prognostic tool, independent of the inflammatory response.

Our study has strengths and limitations. The investigated cohort of CRC patients is large, with a comparably long follow-up time. Review pathology was performed independently by two experienced gastrointestinal pathologists. Foremost are the limitations inherent to retrospective analyses, and patients underwent surgery by multiple surgeons from both academic and community settings. In addition, budding was assessed only on haematoxylin and eosin stained slides, and anti-cytokeratin immunohistochemistry was not applied in this study.

In conclusion, high-grade budding assessed on haematoxylin and eosin stained slides is a powerful predictor of outcome in CRC. Inflammation-related destruction of invading cancer islets is able to stratify cases with high-grade budding into two distinct prognostic groups, but it seems to have a minor role in cases with low-grade budding.
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![**Tumour budding, defined as the presence of isolated single cells or small clusters of cells (composed of fewer than five cells), in a case with no increase of inflammatory cells at the invasive tumour margin, illustrated in serial sections stained with haematoxylin and eosin (**A**; original × 100) and anti-cytokeratin immunohistochemistry (**B**; original × 100).** Marked peritumoural inflammation, leading to the presence of isolated cancer cells due to destruction of invading cancer cell islets, is shown in serial sections stained with haematoxylin and eosin (**C**; original × 100) and anti-cytokeratin immunohistochemistry (**D**; original × 100).](bjc2015454f1){#fig1}

![**Combined analysis of tumour budding and overall peritumoural inflammation.** Patients with high-grade budding and marked inflammation had a better outcome, with respect to both progression-free (*P*\<0.001) and cancer-specific survival (*P*\<0.001), than patients with high-grade budding and only mild inflammation. Outcome in these cases, however, was still worse compared with patients with low-grade budding, in which the extent of peritumoural inflammation had no further prognostic effect.](bjc2015454f2){#fig2}

###### Association of tumour budding with other pathological variables (tumour size was known for 360 patients)

                         **N**   **Low-grade budding (*****n*****=221)**   **High-grade budding (*****n*****=160)**   ***P*****-value**
  ---------------------- ------- ----------------------------------------- ------------------------------------------ -------------------
  **T classification**                                                                                                
  T1                     28      27 (96.4%)                                1 (3.6%)                                   \<0.001
  T2                     70      55 (78.6%)                                15 (21.4%)                                  
  T3                     218     119 (54.6%)                               99 (45.4%)                                  
  T4a                    15      7 (46.7%)                                 8 (53.3%)                                   
  T4b                    50      13 (26%)                                  37 (74%)                                    
  **N classification**                                                                                                
  N0                     213     164 (77%)                                 49 (23%)                                   \<0.001
  N1a                    43      27 (62.8%)                                16 (37.2%)                                  
  N1b                    40      12 (30%)                                  28 (70%)                                    
  N2a                    39      8 (20.5%)                                 31 (79.5%)                                  
  N2b                    46      10 (21.7%)                                36 (78.3%)                                  
  **Grade**                                                                                                           
  G1                     121     103 (85.1%)                               18 (14.9%)                                 \<0.001
  G2                     138     67 (48.6%)                                71 (51.4%)                                  
  G3                     122     51 (41.8%)                                71 (58.2%)                                  
  **Inflammation**                                                                                                    
  Score 0                11      5 (45.5%)                                 6 (54.5%)                                  0.016
  Score 1                156     80 (51.3%)                                76 (48.7%)                                  
  Score 2                146     86 (58.9%)                                60 (41.1%)                                  
  Score 3                68      50 (73.5%)                                18 (26.5%)                                  
  **Tumour size**                                                                                                     
  ⩽4.5 cm                202     123 (60.9%)                               79 (39.1%)                                 0.33
  \>4.5 cm               158     88 (55.7%)                                70 (44.3%)                                  
  **Tumour location**                                                                                                 
  Right                  107     60 (55.7%)                                47 (44.3%)                                 0.75
  Left                   110     67 (60.9%)                                43 (39.1%)                                  
  Rectum                 164     94 (57.3%)                                70 (42.7%)                                  
